Want to see AU:MSB full AI Analyst Report?
MSB Stock Chart & Stats
AU$2.25
-AU$0.15(-5.07%)
At close: 4:00 PM EST
AU$2.25
-AU$0.15(-5.07%)
Day’s Range― - ―
52-Week RangeAU$1.88 - AU$3.31
Previous CloseN/A
Volume5.54M
Average Volume (3M)4.33M
Market Cap
AU$3.16B
Enterprise ValueAU$3.52K
Total Cash (Recent Filing)AU$129.57M
Total Debt (Recent Filing)AU$135.14M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,296,862,800
10 Day Avg. Volume4,518,407
30 Day Avg. Volume4,325,729
Financial Highlights & Ratios
PEG Ratio-27.18
Price to Book (P/B)2.09
Price to Sales (P/S)72.48
P/FCF Ratio-24.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.84Price Target Upside70.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$200.94M
Bulls Say, Bears Say
Bulls Say
Commercial Launch & Revenue GrowthA material commercial launch providing immediate product-derived revenue establishes an early commercial foothold and real-world demand signals. Durable adoption in pediatric centers and a planned adult label expansion create a multi-year revenue runway that supports reinvestment and scale.
Very High Gross MarginsSustained ~93% gross margins indicate strong product pricing power or low variable cost per treatment at current scale. High gross margins provide structural ability to fund R&D and commercial expansion, absorb SG&A, and improve profitability as fixed costs are leveraged over higher volumes.
Broad Payer Coverage & Rapid Center OnboardingExtensive reimbursement coverage and quick formulary listings materially lower commercialization barriers. Durable payer access and concentrated treatment centers enable predictable reimbursement flows and faster patient uptake, supporting sustainable revenue growth across geographies and payers.
Bears Say
Revenue Concentration RiskDependence on a single product for nearly all current revenues creates structural vulnerability: regulatory, manufacturing, or competitive setbacks to Ryoncil would disproportionately affect cash flow and valuation. Diversification from pipeline successes is required to reduce this single-product exposure.
Negative Operating Cash Flow & Ongoing LossesPersistent operating cash deficits and ongoing net losses indicate the company still consumes cash despite commercial revenue. Sustained cash burn elevates reliance on non-dilutive financing, credit tranches, or future milestones, placing execution pressure on converting launch momentum into positive operating cash flow.
Manufacturing, CMC And Regulatory Execution RiskComplex cell-therapy CMC validation and pending potency assay work are structural execution risks that can delay BLA filings or constrain supply scale-up. Such delays increase development costs, slow revenue diversification across indications, and can require additional time and capital to resolve.
Mesoblast Limited News
MSB FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest share price was AU$1.88 and its highest was AU$3.31 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is AU$3.16B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is Sep 02, 2026 which is in 45 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.044 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.034.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is >-0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,296,862,800 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -AU$0.044 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went down -7.589%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in AU:MSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$3.84 (70.67% Upside)
AU$3.84 (70.67% Upside)
Blogger Sentiment
Bullish
AU:MSB Sentiment 96%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.82%
12-Months-Change
Fundamentals
Return on Equity
-14.02%
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology, hematology, and immune-mediated and inflammatory disorders. Mesoblast's distinctive regenerative medicine platform is founded on the therapeutic potential of specialized mesenchymal lineage cells. A prominent candidate, Remestemcel-L, is currently in late-stage (Phase III) clinical trials for various systemic inflammatory conditions, such as steroid-refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic-refractory inflammatory bowel disease. Additionally, Remestemcel-L is undergoing Phase III evaluation for chronic heart failure and chronic low back pain linked to degenerative disc disease. The company's pipeline also features MPC-300-IV, under development for biologic-refractory rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC, aimed at treating or preventing acute myocardial infarction. Mesoblast has forged key strategic partnerships, including one with Tasly Pharmaceutical Group for the commercialization of MPC-150-IM (for heart failure) and MPC-25-IC (for heart attacks) in China. It also collaborates with JCR Pharmaceuticals Co. Ltd. on wound healing therapies for epidermolysis bullosa patients, and with Grünenthal to advance and market a cell therapy for chronic low back pain.
MSB Stock 12 Month Forecast
Average Price Target
AU$3.84
▲(70.67% Upside)
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―